PubMed Health⌕ Search

PubMed · 10762890

Changes in Left Ventricular Function After Coronary Recanalization by Percutaneous Transluminal Coronary Angioplasty (PTCA).

Abstract

Forty-six patients (21 with stable angina and 25 with chronic myocardial infarction, 37 men) with a total chronic proximal coronary occlusion and collateral vessels to the distal part of the occluded artery (30 LAD, 10 RCA and 6 CX properly distributed in both groups) were studied angiographically before and 2 to 8 months (mean 6) after balloon angioplasty. The patients were divided in six subgroups: A) Angina pectoris no matter the result of recanalization (n = 21); B) Myocardial infarction no matter the result of recanalization (n = 25); C) Angina pectoris with successful recanalization and open coronary (O.C.) > 50% at follow-up (n = 13); D) Angina pectoris with unsuccessful recanalization and/or restenosis or closed coronary (C.C.) at follow-up (n = 8); E) Myocardial infarction with successful recanalization and O.C. > 50% at follow-up (n = 8); F) Myocardial infarction with unsuccessful recanalization and/or restenosis or C.C. at follow-up (n = 17). No subgroup showed statistical differences (p > 0.05) in LVEDP before (B) and at follow-up (FU). On the other hand, several measurements were statistically different in the subgroup A at B and at FU: Ejection fraction (EF) [57.3 +/- 12.3 and 64.2 +/- 19.4%; p = 0.02]; Regional wall motion (RWM) measured in the region of the affected coronary [18.7 +/- 9.6 and 23.6 +/- 11.8%; p = 0.05]; Minimal wall motion (MWM) measured in the site of lesser parietal movement [14.3 +/- 13.1 and 25.8 +/- 26.2%; p = 0.02]. In the subgroup C the following differences were observed: EF [58.4 +/- 12.3 and 69.0 +/- 12.4%; p = 0.003]; RWM [16.3 +/- 8.4 and 25.4 +/- 8.2%; p = 0.005]; MWM [14.7 +/- 15.1 and 27.9 +/- 18.0%; p = 0.0001]. In the other considered subgroups we did not reach significant differences (p > 0.05) in these measurements. We conclude that recanalization of a chronic coronary occlusion improves left ventricular contractile function in the presence of viable myocardium and that MSF is the most sensitive among the studied variables to separate anginal patients from the patients without viable myocardium after successful recanalization.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

CA Gottschall, I Trindade, V Miler. 1997. Changes in Left Ventricular Function After Coronary Recanalization by Percutaneous Transluminal Coronary Angioplasty (PTCA).. https://pubmed.ncbi.nlm.nih.gov/10762890/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗